EARLY VERSUS LATE STEROID WITHDRAWAL Julio Pascual, Barcelona, Spain Chairs: Ryszard Grenda, Warsaw, Poland
|
|
- Chrystal Atkins
- 6 years ago
- Views:
Transcription
1 EARLY VERSUS LATE STEROID WITHDRAWAL Julio Pascual, Barcelona, Spain Chairs: Ryszard Grenda, Warsaw, Poland Julio Pascual, Barcelona, Spain Prof. Julio Pascal Hospital del Mar Nephrology Department Barcelona, Spain Slide 1 Ladies and gentlemen, dear chairman, I'm not Julio Pascual, he unfortunately couldn't come due to family matters and asked me two days ago whether it would be possible to present his talk. So I agreed but I certainly cannot replace Julio who is a really too much of an expert in that field but again he sent me his slides so I will try to do my best. Slide2
2 It's a topic that's always hot and is always a topic that is open for discussion simply because there are no clear answers. If it were clear, there wouldn't be any reason to discuss it. Slide 3 What is the reason that steroids are used in transplantation? First of all, we all know they're used for prophylaxis, for acute rejection, they exhibit immunosuppressive effects, they are frequently or standard used in the treatment of rejections, and they are also probably useful for prevention of chronic rejection. So what is the reason to why we think we may be able to withdraw them? Because there are some side effects attached to it. Slide 4
3 In the short term there's weight gain, which is never very good, there is sometimes as what's listed here PTDM or NODAT, new onset diabetes after transplantation, it's highly associated with wound healing problems, sometimes it's GI problems and nevertheless emotional disturbances and other severe problems. There are long-term issues. The cumulative dose of steroids should not be underestimated, specifically if you talk about bone disease, osteoporosis, hypotension, the long consequences of post-transplant diabetes and also, visibility might be impacted by a cataract and psychiatric disorders. So what's the balance on that? Slide 5 Why should we consider to use steroids or stop them? To minimise adverse effects without increasing acute rejection or chronic loss of function. This would be the ideal world.
4 Slide 6 Now he actually separated his talk into two parts. The first part will be about the withdrawal of steroids in the long run, so after a month. He coined this 'late withdrawal' and I will speak about that first. The second part is about what he calls 'avoidance', which is only a few days immediately after transplantation the use of steroids and then immediate cessation. Slide 7 Now let's start with the late withdrawal. Slide 8
5 In the early days so to speak, more than 10 years ago. Bert Kasiske published his first metaanalysis, which is a compound analysis on all the randomised trials that were available then, and I think it's a very useful tool in terms of getting a clear impact or a clear answer on the intervention. What it basically shows on the outcome of acute rejection and the studies that were at that time available, I think it was clear that if you withdraw steroids in combination with cyclosporine that's an important issue, in combination with cyclosporine and CellCept, you actually had a higher risk of acute rejection which was in the range of about 10-20%. Slide 9 The meta-analysis also found a more important risk of graft loss. The risk for graft loss was increased by almost 4%. It's a relative risk, so it's not the absolute risk but still it's a huge impact on long-term outcomes. So from that point of view steroid withdrawal would not have been recommended. But again keep in mind it's more than 15 years ago because the studies that are listed here, some of them were years ago. So they were all done in combination with cyclosporine. Slide 10
6 Now, what I said initially that steroids are able to suppress the inflammatory response of the alloimmune graft you see here the Brian Nankivell protocol biopsy study showing that if you withdraw steroids in combination with cyclosporine and azathioprine, you actually experience what he calls 'subclinical acute rejection' in the range of about 60% which is actually a very high range. However, in the newer combination with tacrolimus and MMF it's actually initially high but then it weans off and at 12 months you have virtually no subclinical acute rejection in the protocol biopsies suggesting that if you use a standard immunosuppressive regimen with tacrolimus Cellcept, it might easily be possible to withdraw cyclosporine after a couple of months after transplantation. Slide 11 Now there are other control trials. Julio actually published 8 years ago 9 years ago another meta-analysis with the new trials on cyclosporine, or tacrolimus plus MMF and he actually found the same estimates. So the risk was even higher when the trials were mixed. So, the conclusion is not so clear from this meta-analysis but keep in mind again that this was published 10 years ago.
7 Slide 12 However, he did not observe the same effect on graft loss that Bert Kasiske did which is I think important. Slide 13
8 Now what he found was that some proxy markers or biomarkers for atherosclerosis such as total cholesterol were lower in the group where steroids were withdrawn. Now that's not unexpected I would say but we don't know whether this actually has an impact on for example, mortality, cardiac arrest, stroke or atherosclerotic comorbidities, that's unclear. Slide 14 Now what did the KDOQI guidelines say four years ago? Point 3.2 says if prednisolone is being used beyond the first week after transplantation, we suggest to keep it rather than withdraw it but again this was almost now more than 4 or 5 years ago, maybe this has changed. Slide 15 Now there's one meta-analysis from Julio done together with the Cochrane group in Sidney and one of my co-workers Maria Haller who is here spent the last year updating this review, data not quite available but I hope it will be next year. Slide 16
9 So what's the recommendation from their point of view? So withdrawal after the first 3-6 months is safe. If you have a patient with a low immunological risk and on immunosuppression that's basically on tacrolimus and MMF. However, with cyclosporine one experiences more rejections. It seems that with tacrolimus these problems are not so severe. You may have an impact on the cardiovascular risk profile as evidenced by the lower or decrease in cholesterol. However, nobody knows whether this actually impacts on hard outcomes. No controlled evaluation beyond 3 years is available. So it's still open to discussion. Slide 17 Now what about the very early stop of cyclosporine the so-called 'steroid avoidance strategy' which is one of the favourite protocols in the United States? Slide 18
10 A recent paper from Julio Pascual actually investigated the available 9 trials with the same design Slide 19 like a systemic review and these are the main results from the paper. Now if you have steroid avoidance protocols within the first 2 weeks, he identified 9 trials as I said, there was no impact whatsoever on hard outcomes such as death. You see the relative risk is close to 1. There was no impact on graft loss including death, which is the actual graft loss. There was no impact whatsoever on death censored or functional graft loss. However, biopsy proven acute rejections were more frequently seen before in the cyclosporine groups. So the risk was almost 2-fold but there was no statistical risk in tacrolimus. One conclusion or one lesson from this would be that obviously early acute rejections do not impact on long-term graft survival because otherwise it wouldn't have been explainable that you have a twiceincreased risk of acute rejection but no differences in graft loss. Again, other measures proxy or steroid use were beneficial but it remains to be determined what this means in the longterm. Slide 20
11 Another group or group from Arthur Matas in the United States from Minnesota, his group is using steroid withdrawal very early on for a long period of time and he published recently in the CJASN a paper where he compared the results from Minnesota on the patients that had steroid avoidance with historical controls. Now there are some issues, some statistical issues that if you use historic controls. For some people doing a randomised controlled trial in randomised people is not the same. There's also something that's called the era effect that for example that the overall mortality decreased over years for several other reasons, for people smoking, for better cars whatsoever. So it's very hard actually to compare those groups. So certainly in a univariate analysis using just Kaplan-Meier analysis. Nevertheless, what he showed is that the steroid avoidance group in the solid line compared to the historical controls Slide 21 in the dash line was not different in terms of graft survival. There was no difference in functional graft survival whether it was live donors or deceased donors. Actually, for the deceased donors he found that their sense of graft survival was actually better if steroids were withdrawn. Now the only explanation for that was probably that there was a selection bias because one would not expect that the graft survival is actually better if you withdraw the functional graft survival, if you withdraw the steroids. Slide 22
12 Now Slide 23 what is the KDIGO suggestion from 2009? Point 2.4 they suggest that in patients who are at low immunological risk and who receive induction therapy steroids could be discontinued during the first week after transplantation but again the statement says 'if they're receiving induction therapy'. It depends on what you're using. Most of the centres in the USA are using Campath now. In most of European countries Campath is not the first line induction therapy, it's usually an IL2 antagonist. Whether that's true for the IL2 antagonist, I'm not quite sure. Slide 24
13 Now what do they recommend? They would recommend, as in most of the conclusions stated, to do a randomised trial. There should be long term randomized controlled trials with adequate statistical power to detect differences in early rejection, adverse events but also in the long run. Now this probably will never happen as we know and it's very hard to power a trial to actually find the differences in long term outcomes and the real culprit with this is that it can only test one time point. You say is it possible to withdraw at week 1, 2 of month 3? And then you get a result for one time point but you still don't know when the optimal time point is. Maybe the optimal time point is at I don't know 4 months. Slide 25 This is actually a question that Maria tried to address and she used large databases where people were withdrawn at different time points. There were people that were withdrawn at 3 months, one week, two years and so on so continuous withdrawal of steroids and certainly there's usually a reason why people are withdrawn. So you have to account for that and there are statistical tools to address this issue. One is called the propensity score matching which is basically a retrospective matching of people that got withdrawn versus people that were still maintained on steroids. Then you can do what's called land marking to test for different time points whether the patients that survived until this time point had a higher risk of graft loss or a lower risk of graft loss if steroids were withdrawn. You see in the first almost year if you withdraw steroids, you have a higher risk and ---- hard outcome of actual graft
14 loss which is a combination of death and graft loss. Then after the first year that's a 6 curve the risk decreases to half predominantly because the mortality decreases somehow. I think that's a very, very interesting observation suggesting that probably it's wise to keep steroids for the first year or somewhere around the first year and then try to wean them off. Then you have the maximal protection in the first couple of months and not the long run toxicity. But again, that's an observational study with all the limitations of an observational study. Slide 26 Now what is Julio's conclusion? Steroids he says may be withdrawn in many patients without any problems. So better than a new large randomised trial he wants to have more answers to specific questions whether first of all is the dose we're using in the long run 5 mg/day of prednisolone impact on long term problems such as severe risks? Is there an immune phenotype of high responders that will develop acute or chronic rejection after withdrawal? So in other words is there a biomarker? Probably yes with DSA for example. To stimulate indirect antigen recognition de novo HLA antibodies or other alloimmune response after withdrawal that remains to be determined. Slide 27
15 Now again I gave this talk on behalf of Julio who unfortunately has a major family issue and could not come and I hope I was able to replace in somehow. Thank you very much.
DRUG LEVEL MONITORING AND ADJUSTMENT Silvio Sandrini, Brescia, Italy Chairs: Ryszard Grenda, Warsaw, Poland Julio Pascual, Barcelona, Spain
DRUG LEVEL MONITORING AND ADJUSTMENT Silvio Sandrini, Brescia, Italy Chairs: Ryszard Grenda, Warsaw, Poland Julio Pascual, Barcelona, Spain Prof. Silvio Sandrini Division and Chair of Nephrology University
More informationmtor inhibitors lights and shadows Giuseppe Grandaliano, Foggia, Italy Chairs: Turgay Arinsoy, Ankara, Turkey Josep M. Grinyo, Barcelona, Spain
mtor inhibitors lights and shadows Giuseppe Grandaliano, Foggia, Italy Chairs: Turgay Arinsoy, Ankara, Turkey Josep M. Grinyo, Barcelona, Spain Prof. Giuseppe Grandaliano Nephrology Department Faculty
More informationWhat is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham
What is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham SYMPHONY Study Ekberg et al. NEJM 2008 Excluded: DCD kidneys; CIT>30hours;
More informationAndrew Schorr: Dr. Young, for patients receiving initial treatment could you discuss the findings comparing horse ATG and rabbit ATG?
What s New in Aplastic Anemia Treatment American Society of Hematology Meeting December 2011 Dr. Neal S. Young Please remember the opinions expressed on Patient Power are not necessarily the views of our
More informationSteroid Minimization: Great Idea or Silly Move?
Steroid Minimization: Great Idea or Silly Move? Disclosures I have financial relationship(s) within the last 12 months relevant to my presentation with: Astellas Grants ** Bristol Myers Squibb Grants,
More informationSection 4 Decision-making
Decision-making : Decision-making Summary Conversations about treatments Participants were asked to describe the conversation that they had with the clinician about treatment at diagnosis. The most common
More informationPREVENTION AND TREATMENT OF BKV NEPHROPATHY Petra Reinke, Berlin, Germany. Chair: Daniel Abramowicz, Brussels, Belgium Rosanna Coppo, Turin, Italy
PREVENTION AND TREATMENT OF BKV NEPHROPATHY Petra Reinke, Berlin, Germany Chair: Daniel Abramowicz, Brussels, Belgium Rosanna Coppo, Turin, Italy Prof Petra Reinke Department of Nephrology University Hospital
More informationAmerican Journal of Transplantation 2009; 9 (Suppl 3): S1 S157 Wiley Periodicals Inc.
American Journal of Transplantation 2009; 9 (Suppl 3): S1 S157 Wiley Periodicals Inc. 2009 The Authors Journal compilation 2009 The American Society of Transplantation and the American Society of Transplant
More informationControversies in Renal Transplantation. The Controversial Questions. Patrick M. Klem, PharmD, BCPS University of Colorado Hospital
Controversies in Renal Transplantation Patrick M. Klem, PharmD, BCPS University of Colorado Hospital The Controversial Questions Are newer immunosuppressants improving patient outcomes? Are corticosteroids
More informationProf. Armando Torres Nephrology Section Hospital Universitario de Canarias University of La Laguna Tenerife, Canary Islands, Spain.
Does RAS blockade improve outcomes after kidney transplantation? Armando Torres, La Laguna, Spain Chairs: Hans De Fijter, Leiden, The Netherlands Armando Torres, La Laguna, Spain Prof. Armando Torres Nephrology
More informationThe Current Research on Stretching and Flexibility is Flawed!
Transcript from: https://www.youtube.com/watch?v=qz0ot7tbbg0 Original Article: http://stretchcoach.com/articles/proper-stretching/ The Current Research on Stretching and Flexibility is Flawed! Hi. I'm
More informationAutoimmune disorders: An emerging risk factor for CV disease
Autoimmune disorders: An emerging risk factor for CV disease DR. SHARON MULVAGH: Greetings. I'm Dr Sharon Mulvagh, professor of medicine and director of Mayo Clinic Women's Heart Clinic. During today's
More informationPROSTATE CANCER SCREENING SHARED DECISION MAKING VIDEO
PROSTATE CANCER SCREENING SHARED DECISION MAKING VIDEO 1 00:00:00,067 --> 00:00:10,968 2 00:00:10,968 --> 00:00:12,701 So, you were given a decision aid sheet 3 00:00:12,701 --> 00:00:14,567 about prostate
More informationRoles of Non-HDL Cholesterol in Risk Assessment and Treatment
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/lipid-luminations/roles-of-non-hdl-cholesterol-in-risk-assessment-andtreatment/7066/
More informationRyszard Grenda: Steroid-Free Pediatric Transplantation. Early Steroid Withdrawal in Pediatric Renal Transplantation
Trends in Transplant. 2011;5:115-20 Ryszard Grenda: Steroid-Free Pediatric Transplantation Early Steroid Withdrawal in Pediatric Renal Transplantation Ryszard Grenda Department of Nephrology, Kidney Transplantation
More informationProf. Rosanna Coppo Director of the Nephrology, Dialysis and Transplantation Department Regina Margherita Hospital Turin, Italy. Slide 1.
ROLE OF PATHOLOGY AND CLINICAL FEATURES IN PREDICTING PROGRESSION OF IGA NEPHROPATHY: RESULTS FROM THE ERA-EDTA RESEARCH VALIGA Rosanna Coppo, Turin, Italy Chairs: François Berthoux, Saint-Etienne, France
More informationLiterature Review: Transplantation July 2010-June 2011
Literature Review: Transplantation July 2010-June 2011 James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver Kidney Transplant Top 10 List: July Kidney
More informationOverview of New Approaches to Immunosuppression in Renal Transplantation
Overview of New Approaches to Immunosuppression in Renal Transplantation Ron Shapiro, M.D. Professor of Surgery Surgical Director, Kidney/Pancreas Transplant Program Recanati/Miller Transplantation Institute
More informationProf. Sandrine Florquin Department of Pathology Academic Medical Center University of Amsterdam Amsterdam, The Netherlands. Slide 1.
Interleukin 17 in renal biopsies as risk factor for progression Sandrine Florquin, Amsterdam, The Netherlands Chairs: Mohamed R. Daha, Leiden, The Netherlands Pierre Ronco, Paris, France Prof. Sandrine
More informationSmoking Cessation Strategies for the 21st Century
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/lipid-luminations/smoking-cessation-strategies-for-the-21stcentury/3862/
More informationWhy Do We Need New Immunosuppressive Agents
Why Do We Need New Immunosuppressive Agents 1 Reducing acute rejection rates has not transplanted into better long-term graft survival Incidence of early acute rejection episodes by era Relative risk for
More informationASCO 2016: Ask the Lung Cancer Experts
Live @ ASCO 2016: Ask the Lung Cancer Experts Charu Aggarwal, MD, MPH Assistant Professor of Medicine University of Pennsylvania Health System Liza Villaruz, MD Hematology/Oncology Specialist University
More informationSELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%
SELECTED ABSTRACTS The following are summaries of selected posters presented at the American Transplant Congress on May 5 9, 2007, in San Humar A, Gillingham KJ, Payne WD, et al. Review of >1000 kidney
More informationWhy Are So Many Clinicians Choosing to Practice Functional Medicine?
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/integrative-and-functional-medicine-in-practice/why-are-so-manyclinicians-choosing-practice-functional-medicine/8424/
More informationThe Sun is Setting for Sulfonylureas - Frankly Speaking EP 40
The Sun is Setting for Sulfonylureas - Frankly Speaking EP 40 Transcript Details This is a transcript of an episode from the podcast series Frankly Speaking accessible at Pri- Med.com. Additional media
More informationANAEMIA MANAGEMENT: THE KDIGO RECOMMENDATIONS Patrick S. Parfrey, St. John s, Canada
ANAEMIA MANAGEMENT: THE KDIGO RECOMMENDATIONS Patrick S. Parfrey, St. John s, Canada Chair: Kai- Uwe Eckardt, Erlangen, Germany Pierre- Yves Martin, Geneva, Switzerland Prof. Patrick S. Parfrey Division
More informationANAEMIA MANAGEMENT: HOW AND WHY DOES ERBP DIFFER FROM KDIGO Francesco Locatelli, Lecco, Italy
ANAEMIA MANAGEMENT: HOW AND WHY DOES ERBP DIFFER FROM KDIGO Francesco Locatelli, Lecco, Italy Chair: Kai- Uwe Eckardt, Erlangen, Germany Pierre- Yves Martin, Geneva, Switzerland Prof. Francesco Locatelli
More informationProf. David Wheeler Centre for Nephrology Royal Free Campus University College London Medical School London, UK. Slide 1
LDL-CHOLESTEROL AND CV RISK IN CKD: EPIDEMIOLOGY VS. CLINICAL TRIALS David Wheeler, London, UK Chairs: Maurice Laville, Lyon, France Erling B. Pedersen, Holstebro, Denmark Prof. David Wheeler Centre for
More informationClinical Trials: Non-Muscle Invasive Bladder Cancer. Tuesday, May 17th, Part II
Clinical Trials: Non-Muscle Invasive Bladder Cancer Tuesday, May 17th, 2016 Part II Presented by Yair Lotan, MD is holder of the Helen J. and Robert S. Strauss Professorship in Urology and Chief of Urologic
More informationDr. Gopal, are you encouraged in the direction of where research is headed and its benefit for patients?
Targeting the Tumor in Lymphoma July 8, 2009 Ajay Gopal Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle Cancer Care Alliance, its medical staff or Patient
More informationOrgan rejection is one of the serious
Original Article Outcomes of Late Corticosteroid Withdrawal after Renal Transplantation in Patients Exposed to Tacrolimus and/or Mycophenolate Mofetil: Meta-Analysis of Randomized Controlled Trials A.
More informationLung Transplantation for Cystic Fibrosis
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/cystic-fibrosis-in-focus/lung-transplantation-cystic-fibrosis/8306/
More informationTolerance Induction in Transplantation
Tolerance Induction in Transplantation Reza F. Saidi, MD, FACS, FICS Assistant Professor of Surgery Division of Organ Transplantation Department of Surgery University of Massachusetts Medical School Percent
More informationKidney transplantation 2016: current status and potential challenges
Kidney transplantation 2016: current status and potential challenges 15/12/2016 BVN-SBN : State-of-the-Art on Kidney Transplantation Patrick Peeters Ghent University Hospital, Belgium Challenges in 2016
More informationCHAPTER 3 HEART AND LUNG TRANSPLANTATION. Editors: Mr. Mohamed Ezani Hj Md. Taib Dato Dr. David Chew Soon Ping
CHAPTER 3 Editors: Mr. Mohamed Ezani Hj Md. Taib Dato Dr. David Chew Soon Ping Expert Panel: Tan Sri Dato Dr. Yahya Awang (Chair) Mr. Mohamed Ezani Hj Md. Taib (Co-chair) Datin Dr. Aziah Ahmad Mahayiddin
More informationA Critical View of JUPITER
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/lipid-luminations/a-critical-view-of-jupiter/4124/
More informationMS Learn Online Feature Presentation Stress and MS: What We Know Featuring Fred Foley, Ph.D.
Page 1 MS Learn Online Feature Presentation Stress and MS: What We Know Featuring Fred Foley, Ph.D. >>Kate Milliken: Hello. I'm Kate Milliken and welcome to MS Learn Online. Aside from the stress that
More informationEffect of long-term steroid withdrawal in renal transplant recipients: a retrospective cohort study
NDT Plus (2010) 3 [Suppl 2]: ii32 ii36 doi: 10.1093/ndtplus/sfq064 Effect of long-term steroid withdrawal in renal transplant recipients: a retrospective cohort study Miguel Gonzalez-Molina 1, Miguel Angel
More informationMOLECULAR PREDICTORS OF OUTCOME Ondrej Viklicky, Prague, Czech Republic. Chair: Daniel Abramowicz, Brussels, Belgium Rosanna Coppo, Turin, Italy
MOLECULAR PREDICTORS OF OUTCOME Ondrej Viklicky, Prague, Czech Republic Chair: Daniel Abramowicz, Brussels, Belgium Rosanna Coppo, Turin, Italy Prof Ondrej Viklicky Department of Nephrology Transplant
More informationWhy? "the post workout period that results in metabolic disturbance, elevating EPOC,
Q: What do you look for when designing a fat loss training program? Do you look at what people have done in the gyms before, or do you read the research and then try to recreate that? A: The primary goals
More informationKDBH Podcast #3: American Heart Association s 2018 Cholesterol Guidelines and the Implications for Type 2 Diabetes
Robert Eckel: 00:04 Welcome and thank you for joining us for the third podcast from the new and information podcast series on cardiovascular disease and diabetes for health care professionals. The goal
More informationTRANSCRIPT. Do Corticosteroids Decrease the Pain of Acute Pharyngitis? - Frankly Speaking EP 18
Do Corticosteroids Decrease the Pain of Acute Pharyngitis? - Frankly Speaking EP 18 Transcript Details This is a transcript of an episode from the podcast series Frankly Speaking accessible at Pri- Med.com.
More informationCohen: Well, hi to my listeners, this is Dr. Marc Cohen, and I am happy again to discuss with you advances in the efficacy and safety of TNF
Cohen: Well, hi to my listeners, this is Dr. Marc Cohen, and I am happy again to discuss with you advances in the efficacy and safety of TNF inhibitors. This is a subject of great interest to me and I
More informationIntruduction PSI MODE OF ACTION AND PHARMACOKINETICS
Multidisciplinary Insights on Clinical Guidance for the Use of Proliferation Signal Inhibitors in Heart Transplantation Andreas Zuckermann, MD et al. Department of Cardio-Thoracic Surgery, Medical University
More informationHepatocellular Carcinoma: Clinical Priorities from Detection to Liver Transplantation
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/hepatocellular-carcinomaclinical-priorities-detection-liver-transplantation/7948/
More informationEuropean Risk Management Plan. Measures impairment. Retreatment after Discontinuation
European Risk Management Plan Table 6.1.4-1: Safety Concern 55024.1 Summary of Risk Minimization Measures Routine Risk Minimization Measures Additional Risk Minimization Measures impairment. Retreatment
More informationHow to Work with the Patterns That Sustain Depression
How to Work with the Patterns That Sustain Depression Module 5.2 - Transcript - pg. 1 How to Work with the Patterns That Sustain Depression How the Grieving Mind Fights Depression with Marsha Linehan,
More informationCarrier Screening in your Practice Is it Time to Expand your View?
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-industry-feature/carrier-screening-your-practice-it-time-expandyour-view/9648/
More informationDRUG MINIMISATION FROM BENCH TO BEDSIDE SOME LESSONS FROM THE RISET PROGRAM Hans-Dieter Volk, Berlin, Germany
DRUG MINIMISATION FROM BENCH TO BEDSIDE SOME LESSONS FROM THE RISET PROGRAM Hans-Dieter Volk, Berlin, Germany Chair: Josep M. Grinyo, Barcelona, Spain Marian Klinger, Wroclaw, Poland Prof Hans-Dieter Volk
More informationEmerging Drug List EVEROLIMUS
Generic (Trade Name): Manufacturer: Everolimus (Certican ) Novartis Pharmaceuticals NO. 57 MAY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence: For use with cyclosporine
More informationRisk Factors in Long Term Immunosuppressive Use and Advagraf. Daniel Serón Nephrology department Hospital Universitari Vall d Hebron
Risk Factors in Long Term Immunosuppressive Use and Advagraf Daniel Serón Nephrology department Hospital Universitari Vall d Hebron Progressive well defined diseases ABMR GN Polyoma Non-specific Findings
More informationFH podcast #4 Managing FH Transcript American Heart Association & The FH Foundation
Announcer: 00:02 Welcome. You are listening to a series of four familial hypercholesterolemia podcasts brought to you by the American Heart Association and the FH foundation. This series is focused on
More informationBroadcastMed Bipolar, Borderline, Both? Diagnostic/Formulation Issues in Mood and Personality Disorders
BroadcastMed Bipolar, Borderline, Both? Diagnostic/Formulation Issues in Mood and Personality Disorders BRIAN PALMER: Hi. My name is Brian Palmer. I'm a psychiatrist here at Mayo Clinic. Today, we'd like
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/29755 holds various files of this Leiden University dissertation. Author: Moes, Dirk Jan Alie Roelof Title: Optimizing immunosuppression with mtor inhibitors
More informationGlobal Perspectives on Organ Donation
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/focus-on-global-medicine/global-perspectives-on-organ-donation/3990/
More informationNext Level Practitioner
Next Level Practitioner - Best Advice Week 88, Day 3 - Ed Tronick, PhD - Transcript - pg. 1 Next Level Practitioner Week 88: Treatment Specific Advice Day 3: How Advice Can Change Our Outlook on Our Therapeutic
More informationAdvances in Pediatric Bone Marrow Transplant Webcast March 4, 2011 Scott Baker, M.D., M.S. Anna Robinson. Introduction
Advances in Pediatric Bone Marrow Transplant Webcast March 4, 2011 Scott Baker, M.D., M.S. Anna Robinson Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle
More informationAnswers to Common Physician Questions and Objections
PUSS, RNR PARTNERS IN IMPROVEMENT" Answers to Common Physician Questions and Objections The following document highlights five common questions or objections Consultants, Account Executives and Account
More informationHow to Foster Post-Traumatic Growth
How to Foster Post-Traumatic Growth Module 9 - Transcript - pg. 1 How to Foster Post-Traumatic Growth Are Some Clients Predisposed for Post-Traumatic Growth? with Christine Padesky, PhD; Ron Siegel, PsyD;
More informationSection 4 Decision-making
Decision-making : Experience of health professional communication Conversations about s Participants were asked to describe the conversations they have had about mitochondrial disease options. The most
More informationHealth technology Two prophylaxis schemes against organ rejection in renal transplantation were compared in the study:
An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation Polsky D, Weinfurt K P, Kaplan B, Kim J, Fastenau J, Schulman K A Record Status
More informationBBC Learning English 6 Minute English 2 October 2014 Sleeping on the job
BBC Learning English 6 Minute English 2 October 2014 Sleeping on the job NB: This is not a word for word transcript Hello I'm. Welcome to 6 Minute English. I'm joined today by. Hello..? Hello? Oh sorry,
More informationThis work has been submitted to NECTAR, the Northampton Electronic Collection of Theses and Research.
This work has been submitted to NECTAR, the Northampton Electronic Collection of Theses and Research. Conference or Workshop Item Title: Incentivised smoking cessation intervention with pregnant women:
More informationMinimally Invasive Surgery Offers Promise for Pancreatic Cancer Patients
Minimally Invasive Surgery Offers Promise for Pancreatic Cancer Patients Recorded on: August 1, 2012 Venu Pillarisetty, M.D. Surgical Oncologist Seattle Cancer Care Alliance Please remember the opinions
More informationProf. Franco Ferrario Nephropathology Unit Department of Pathology San Gerardo Hospital Università Milan Bicocca Monza, Italy.
The role of repeated biopsies in the management of Lupus Nephritis Franco Ferrario, Milan, Italy Chairs: David Jayne, Cambridge, UK Vladimir Tesar, Prague, Czech Republic Prof. Franco Ferrario Nephropathology
More informationDivya Jain Arwindekar, DO Transplant Nephrologist Advocate Christ Medical Center & Associates in Nephrology
Divya Jain Arwindekar, DO Transplant Nephrologist Advocate Christ Medical Center & Associates in Nephrology Not a cure to kidney disease, but it is a very effective treatment Patients still have chronic
More informationSignificance of Basiliximab Induction Therapy in Standard-Risk Renal Transplant in Tacrolimus Era: A Meta-Analysis
Significance of Basiliximab Induction Therapy in Standard-Risk Renal Transplant in Tacrolimus Era: A Meta-Analysis Hatem Ali 1,2, Atif Mohiuddin 2,3, Ajay Sharma 2,3, Mohsen El Kosi 2,4 and Ahmed Halawa
More informationCan Angioplasty Improve Quality of Life for CAD Patients?
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/can-angioplasty-improve-quality-of-life-for-cadpatients/4000/
More informationCTS Collaborative Transplant Study
CTS Collaborative Transplant Study Newsletter : February, The year marks the th anniversary of the Collaborative Transplant Study. Credit goes to all participants for their contribution to a priceless
More informationDr. Michael Keating: My Hopes for the Future of CLL Treatment Recorded on December 8, 2014
Patient Power Knowledge. Confidence. Hope. Dr. Michael Keating: My Hopes for the Future of CLL Treatment Recorded on December 8, 2014 Michael Keating, MB, BS Professor of Medicine, Department of Leukemia
More informationHeart Transplantation ACC Middle East Conference Dubai UAE October 21, 2017
Heart Transplantation ACC Middle East Conference Dubai UAE October 21, 2017 Randall C Starling MD MPH FACC FAHA FESC FHFSA Professor of Medicine Kaufman Center for Heart Failure Department of Cardiovascular
More informationDiabetes Remission with Weight Loss - Frankly Speaking EP 49
Diabetes Remission with Weight Loss - Frankly Speaking EP 49 Transcript Details This is a transcript of an episode from the podcast series Frankly Speaking accessible at Pri- Med.com. Additional media
More information5 Quick Tips for Improving Your Emotional Intelligence. and Increasing Your Success in All Areas of Your Life
5 Quick Tips for Improving Your Emotional Intelligence and Increasing Your Success in All Areas of Your Life Table of Contents Self-Awareness... 3 Active Listening... 4 Self-Regulation... 5 Empathy...
More informationClinical Trials: Advanced or Metastatic Bladder Cancer Wednesday June 22 nd, 2016 Part III: Question and Answer
Clinical Trials: Advanced or Metastatic Bladder Cancer Wednesday June 22 nd, 2016 Part III: Question and Answer Questions Answered by Andrea Apolo, MD is a Lasker Clinical Research Scholar and tenure-track
More informationThe Importance of Biomarkers in Asthma Clinical Phenotypes
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/hot-topics-in-allergy/the-importance-of-biomarkers-in-asthma-clinicalphenotypes/3889/
More informationPalliative Care Chat Episode 3_Interview with Jason Webb March 1, 2017
Palliative Care Chat Episode 3_Interview with Jason Webb March 1, 2017 Hello. This is Dr. Lynn McPherson and welcome to Palliative Care Chat, the podcast brought to you by the online Master of Science
More informationProf. Michel Jadoul Cliniques universitaires St-Luc Université Catholique de Louvain Brussels, Belgium. Slide 1
Phosphate and cardiovascular disease beyond CKD: is phosphate a new cholesterol? Michel Jadoul, Brussels, Belgium Chairs: Pablo Urena Torres, Saint-Ouen, France Carmine Zoccali, Reggio Calabria, Italy
More informationClinical Education Initiative SMOKING CESSATION AND HIV. Speaker: Emily Senay, MD
Clinical Education Initiative Support@ceitraining.org SMOKING CESSATION AND HIV Speaker: Emily Senay, MD 6/7/2017 Smoking Cessation and HIV [video transcript] 00:00:08 - [Dr. Senay] I'm going to leave
More informationHow to Foster Post-Traumatic Growth
How to Foster Post-Traumatic Growth Module 7, Part 2 - Transcript - pg. 1 How to Foster Post-Traumatic Growth Two Ways to Ignite Accelerated Growth Part 2: How Your Choice of Language Can Transform an
More informationCatalyst: Human Probiotic Infusion - ABC TV Science
Catalyst: Human Probiotic Infusion - ABC TV Science 8-10 minutes download segment mp4 (average size 10 MB) Quite simply, HPI involves infusing a patient with someone else's faeces. It's a confronting treatment,
More informationConversations: Let s Talk About Bladder Cancer
Understanding Biomarkers Matt Gaslky, MD, Professor of Medicine Icahn School of Medicine at Mount Sinai Piyush Agarwal, MD, Head, Bladder Cancer Section Urological Oncology Branch, National Cancer Institute
More informationFatigue Take Control Part 4
Page 1 Fatigue Take Control Part 4 >>Speaker: Adding exercise to your life is another way to take control of your fatigue. Checking with your doctor prior to starting or changing an exercise program, and
More informationDSA Positive and then To biopsy or not?
DSA Positive and then To biopsy or not? Banff SCT 2017 29 March 2017 Peter Nickerson, MD, FRCPC, FCAHS Flynn Family Chair in Renal Transplantation Professor of Internal Medicine and Immunology Relevant
More informationEFFECT OF ONLINE HAEMODIAFILTRATION ON ALL- CAUSE MORTALITY AND CARDIOVASCULAR OUTCOMES Ercan Ok, Izmir, Turkey
EFFECT OF ONLINE HAEMODIAFILTRATION ON ALL- CAUSE MORTALITY AND CARDIOVASCULAR OUTCOMES Ercan Ok, Izmir, Turkey Chair: Walter H. Hörl, Vienna, Austria Wojciech Zaluska, Lublin, Poland Prof Ercan Ok Division
More informationImmunopathology of T cell mediated rejection
Immunopathology of T cell mediated rejection Ibrahim Batal MD Columbia University College of Physicians & Surgeons New York, NY, USA Overview Pathophysiology and grading of TCMR TCMR is still a significant
More informationEfficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function
ArtIcle Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function Guodong Chen, 1 Jingli Gu, 2 Jiang Qiu, 1 Changxi
More informationAdvanced Cholesterol Testing
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/lipid-luminations/advanced-cholesterol-testing/3027/
More informationAn Oral Fecal Transplant for Lunch?- Frankly Speaking EP 53
An Oral Fecal Transplant for Lunch?- Frankly Speaking EP 53 Transcript Details This is a transcript of an episode from the podcast series Frankly Speaking accessible at Pri- Med.com. Additional media formats
More informationClinical Education Initiative CD4 CD8 CELL RATIOS IN INDIVIDUALS WITH ACUTE AND EARLY HIV INFECTION. Martin Hoenigl, MD
Clinical Education Initiative Support@ceitraining.org CD4 CD8 CELL RATIOS IN INDIVIDUALS WITH ACUTE AND EARLY HIV INFECTION Martin Hoenigl, MD 2/3/2017 CD4 CD8 Cell Ratios in Individuals with Acute and
More informationLiterature Review Transplantation
Literature Review 2010- Transplantation Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs University of
More informationTracking Genetic-Based Treatment Options for Inflammatory Bowel Disease
Tracking Genetic-Based Treatment Options for Inflammatory Bowel Disease Recorded on: June 25, 2013 Melvin Heyman, M.D. Chief of Pediatric Gastroenterology UCSF Medical Center Please remember the opinions
More informationBack to dialysis after graft failure: Transplantectomy or not? Stop immunosuppression?
Back to dialysis after graft failure: Transplantectomy or not? Stop immunosuppression? Laurent WEEKERS CHU SartTilman Layout Introduction Epidemiology A note of caution on causality and bias Patient survival
More informationThe Diagnosis and Management of Anaphylaxis
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/focus-on-allergy/the-diagnosis-and-management-of-anaphylaxis/3919/
More informationThe Latest in Non-Hodgkin Lymphoma News From ASCO
Patient Power Knowledge. Confidence. Hope. The Latest in Non-Hodgkin Lymphoma News From ASCO John Leonard, MD Associate Dean for Clinical Research Weill Cornell Medical College Please remember the opinions
More informationMerkel Cell Carcinoma: Not Just Another Skin Cancer
Merkel Cell Carcinoma: Not Just Another Skin Cancer Merkel cell carcinoma (MCC) is a rare, aggressive, and often fatal neuroendocrine skin cancer. The incidence of MCC has been increasing in recent decades.
More informationYou re listening to an audio module from BMJ Learning. Hallo. I'm Anna Sayburn, Senior Editor with the BMJ Group s Consumer Health Team.
Transcript of learning module Shared decision making (Dur: 26' 13") Contributors: Anna Sayburn and Alf Collins Available online at: http://learning.bmj.com/ V/O: You re listening to an audio module from
More informationHello and welcome to Patient Power sponsored by UCSF Medical Center. I m Andrew Schorr.
The Integrated Approach to Treating Cancer Symptoms Webcast March 1, 2012 Michael Rabow, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of UCSF Medical Center,
More informationOne of the areas where it's certainly made it difference is with the transplantation of the liver. Dr. Roberts thinks so much for joining us.
Benefits and Risks of Living Donor Liver Transplant Webcast May 28, 2008 John Roberts, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of UCSF Medical Center,
More informationPCSK9 Antibodies for Dyslipidemia: Efficacy, Safety, and Non-Lipid Effects
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/lipid-luminations/pcsk9-antibodies-dyslipidemia-efficacy-safety-and-nonlipid-effects/8335/
More informationOUT OF DATE. Choice of calcineurin inhibitors in adult renal transplantation: Effects on transplant outcomes
nep_734.fm Page 88 Friday, January 26, 2007 6:47 PM Blackwell Publishing AsiaMelbourne, AustraliaNEPNephrology1320-5358 2006 The Author; Journal compilation 2006 Asian Pacific Society of Nephrology? 200712S18897MiscellaneousCalcineurin
More information